Market Overview:
The global interleukin inhibitors market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of autoimmune diseases, rising geriatric population, and growing demand for targeted therapies. Based on type, the global interleukin inhibitors market is segmented into interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 3 (IL-3),inter leuken 4 (IL-4), and others. IL-1 is the most common type of cytokine involved in inflammation and is produced by macrophages, neutrophils, and other cells. It plays a major role in innate immunity by activating NFkB pathway and promoting Th1 responses. The IL-2 segment accounted for the second largest share of the global Inter leukekin inhibitors market in 2017 owing to its ability to stimulate T cell proliferation and activation which leads to an increase in cytotoxic activity against cancer cells. Based on application,the global Inter leukekin inhibitors market is segmented into hospital pharmacies, retail pharmacies, online pharmacies,. Hospital pharmacies are expectedto account forthe largest shareof thismarket due toboththe increasing prevalenceof autoimmune diseasesandgrowing demandfor targeted therapiesamong patients hospitalized with such conditions .
Product Definition:
Interleukin inhibitors are a type of medication used to treat autoimmune diseases. They work by blocking the action of interleukins, proteins that play a role in the immune system. By doing this, they can help reduce inflammation and symptoms associated with autoimmune diseases.
Interleukin 1:
Interleukin 1 (IL-1) is a cytokine that was initially identified as a growth factor for B cells and T cells. Interleukin 1 has since been found to be an important cytokine in several immune responses including the adaptive immune response, inflammatory response, and immunological memory. IL-1 is produced by activated T cells as well as B cell stimulation.
Interleukin 2:
Interleukin-2 (IL-2) is a cytokine that belongs to the interleukin family. IL-2 is produced by activated T cells and natural killer cells in response to foreign antigen. It plays an important role in the immune response against tumor necrosis factor, alpha (TNF -alfa), and other related cytokines.
Application Insights:
The other application segment includes the use of interleukin inhibitors for graft-versus-host disease, chronic lymphocytic leukemia, rheumatoid arthritis and multiple sclerosis. The chronic lymphocytic leukemia segment held the largest share in 2017 owing to its high incidence rates worldwide. According to data published by LLS, Inc., in 2018, around 60% of patients with CLL are susceptible to interleukin inhibition therapy; this percentage is expected to increase with the introduction of new products.
The hospital pharmacies segment is anticipated register a significant growth rate over the forecast period due largely on growing awareness about availability of affordable medicines coupled with rising incidences of cancer across the globe. Hospital-based pharmacists are able to administer drugs that may have side effects or interactions during pregnancy which may lead towards complications during childbirth resulting in higher risk for mother and baby mortality if any such drug is not administered properly leading towards an increased demand for interleukin inhibitors among hospital pharmacies globally.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to rising cases of chronic diseases, increasing adoption of healthy lifestyles, and high healthcare expenditure levels in this region. In addition, growing focus on developing novel therapeutics for treatment of various disorders is anticipated to drive growth over the forecast period.
Asia Pacific is estimated to witness lucrative growth over the coming years owing to factors such as improving healthcare infrastructure and economic development in emerging countries like China and India that are majorly driven by interleukin 2 inhibitor sales revenue generation capacity expansion initiatives undertaken by key players operating within Asia Pacific region including Roche; Pfizer; Merck & Co., Inc.; Celgene Corporation; Amgen Inc.; AbbVie Inc.; Biogen Inc.; FUJIFILM Diosynth Biotechnologies UAB; Johnson & Johnson Services India Ltd.
Growth Factors:
- Increasing incidence of autoimmune diseases: The increasing incidence of autoimmune diseases is one of the key growth drivers for the Interleukin inhibitors market. Autoimmune diseases are caused due to the abnormal functioning of the immune system, which leads to inflammation and damage to tissues and organs. There is a growing demand for Interleukin inhibitors for the treatment of various autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, psoriasis, and ulcerative colitis.
- Rising awareness about interleukin inhibitors: The rising awareness about interleukin inhibitors among healthcare professionals and patients is another major growth driver for this market. There is an increasing demand for these drugs owing to their efficacy in treating various autoimmune disorders.
- Technological advancements in interleukin inhibitor therapies: The technological advancements in interleukin inhibitor therapies are another major factor driving the growth of this market. These drugs are becoming increasingly sophisticated with novel mechanisms-of-action being developed on a regular basis. This has led to an increase in their adoption by patients worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Interleukin Inhibitors Market Research Report
By Type
Interleukin 1, Interleukin 2, Interleukin 3, Interleukin 4, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Regeneron Pharmaceuticals, Valeant Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Interleukin Inhibitors Market Report Segments:
The global Interleukin Inhibitors market is segmented on the basis of:
Types
Interleukin 1, Interleukin 2, Interleukin 3, Interleukin 4, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- GlaxoSmithKline
- Novartis
- Johnson & Johnson
- Roche
- Eli Lilly
- AstraZeneca
- Teva Pharmaceutical
- Regeneron Pharmaceuticals
- Valeant Pharmaceuticals
Highlights of The Interleukin Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Interleukin 1
- Interleukin 2
- Interleukin 3
- Interleukin 4
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Interleukin Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Interleukin inhibitors are medications that block the action of certain interleukins. These medications can be used to treat a variety of conditions, including autoimmune diseases, cancer, and infections.
Some of the major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Regeneron Pharmaceuticals, Valeant Pharmaceuticals.
The interleukin inhibitors market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Interleukin Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Interleukin Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Interleukin Inhibitors Market - Supply Chain
4.5. Global Interleukin Inhibitors Market Forecast
4.5.1. Interleukin Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Interleukin Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Interleukin Inhibitors Market Absolute $ Opportunity
5. Global Interleukin Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Interleukin Inhibitors Market Size and Volume Forecast by Type
5.3.1. Interleukin 1
5.3.2. Interleukin 2
5.3.3. Interleukin 3
5.3.4. Interleukin 4
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Interleukin Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Interleukin Inhibitors Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Interleukin Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Interleukin Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Interleukin Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Interleukin Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Interleukin Inhibitors Demand Share Forecast, 2019-2026
9. North America Interleukin Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Interleukin Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Interleukin Inhibitors Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Interleukin Inhibitors Market Size and Volume Forecast by Type
9.7.1. Interleukin 1
9.7.2. Interleukin 2
9.7.3. Interleukin 3
9.7.4. Interleukin 4
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Interleukin Inhibitors Demand Share Forecast, 2019-2026
10. Latin America Interleukin Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Type
10.7.1. Interleukin 1
10.7.2. Interleukin 2
10.7.3. Interleukin 3
10.7.4. Interleukin 4
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Interleukin Inhibitors Demand Share Forecast, 2019-2026
11. Europe Interleukin Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Interleukin Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Interleukin Inhibitors Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Interleukin Inhibitors Market Size and Volume Forecast by Type
11.7.1. Interleukin 1
11.7.2. Interleukin 2
11.7.3. Interleukin 3
11.7.4. Interleukin 4
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Interleukin Inhibitors Demand Share, 2019-2026
12. Asia Pacific Interleukin Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Type
12.7.1. Interleukin 1
12.7.2. Interleukin 2
12.7.3. Interleukin 3
12.7.4. Interleukin 4
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Interleukin Inhibitors Demand Share, 2019-2026
13. Middle East & Africa Interleukin Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Type
13.7.1. Interleukin 1
13.7.2. Interleukin 2
13.7.3. Interleukin 3
13.7.4. Interleukin 4
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Interleukin Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Interleukin Inhibitors Market: Market Share Analysis
14.2. Interleukin Inhibitors Distributors and Customers
14.3. Interleukin Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GlaxoSmithKline
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Roche
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AstraZeneca
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Teva Pharmaceutical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Regeneron Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Valeant Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
